Physician profile
Aimee Jacobs
NPI 1871969949
$9,887.19
in general payments reported to CMS, 2019-2025
25 companies · $2,975 in 2025
The $2,975 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $513 · 2021: $1,657 · 2022: $1,098 · 2023: $810 · 2024: $865 · 2025: $2,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,505 · Food and Beverage: $2,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,505.20 |
| Food and Beverage | $2,145.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,099.23 | 2019-2024 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $2,995.98 | 2019-2025 | Cvi Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $603.13 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $523.84 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $378.57 | 2022-2025 | Miebo, Xiidra, Infuse |
| Sun Pharmaceutical Industries INC. | $361.05 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $318.48 | 2021 | |
| Biotissue Holdings INC. | $222.13 | 2024-2025 | |
| Maculogix, INC. | $208.39 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $201.31 | 2019-2023 | |
| Oyster Point Pharma, INC. | $160.71 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $124.67 | 2021 | |
| Allergan, INC. | $121.06 | 2020-2022 | |
| Abbvie INC. | $102.52 | 2022-2024 | |
| Eyevance Pharmaceuticals LLC | $102.38 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $76.94 | 2019 | |
| Harrow Eye, LLC | $42.47 | 2024 | Vevye |
| Alcon Research LLC | $38.73 | 2019 | |
| Glaukos Corporation | $37.88 | 2023 | |
| Mallinckrodt Hospital Products INC. | $34.30 | 2021 | |
| Genzyme Corporation | $28.46 | 2024 | |
| Mallinckrodt Enterprises LLC | $28.41 | 2019 | |
| Dompe US, INC. | $26.47 | 2024 | Oxervate |
| Integra Lifesciences Corporation | $26.30 | 2024 | Biodoptix, Biofix, Medihoney |
| Alexion Pharmaceuticals, INC. | $23.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.